Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

Featured MASLD/MASH Educators

Kate Lee-Young

CRNP, DNP

Kate Lee-Young, DNP, MS, CRNP is a board-certified Adult/Gerontology Primary Care Nurse Practitioner specializing in Hepatology and Transplant Hepatology at Johns Hopkins in Baltimore. She earned her MSN and Doctor of Nursing Practice degrees from the University of Maryland and completed an NP Fellowship in Gastroenterology and Hepatology at the Johns Hopkins Hospital. She has a special interest in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Associated Steatohepatitis (MASH) along with obesity management and holds a Certificate of Advanced Education in Obesity Medicine through the Obesity Medicine Association.

Lucy Matthew

NP

Lucy Mathew, NP, is a nurse practitioner at Cedars-Sinai Medical Center, specializing in providing expert care for patients with complex medical conditions. With a focus on personalized treatment and patient education, she is dedicated to improving health outcomes through evidence-based practices.

play

Gabriella McCarty

NP-C

Gabriella McCarty is a gastroenterology/hepatology nurse practitioner. She obtained her masters and nurse practitioner degree at Case Western Reserve University in 2004. She has been practicing in this field for 26 years. She serves as faculty for Gastroenterology/ Hepatology Advanced Practice Providers (GHAPP) and is an American College of Gastroenterology (ACG) committee member, serving on the education subcommittee. She will be completing her doctorate of nursing in May 2025. She loves all aspects of GI / Hepatology, education and nursing.

MASLD/MASH Learning Center

Latest News & Blogs

Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide

July 2025

CONCLUSION: These post hoc analyses suggest that tirzepatide was consistently associated with improved MASH resolution without worsening of fibrosis across subgroups defined by demographics, histology, and biomarkers, compared with placebo.

Read More arrow

Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease

July 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than a quarter of the adult population worldwide. MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH), which is associated with increased risk of progression to liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as cardiovascular complications. The pathogenesis of MASLD is complex and initiated by altered metabolic signalling circuits between the adipose tissue, muscle, gut and...

Read More arrow

A Real-World Experience With Resmetirom: Tolerability and Access

July 2025

CONCLUSION: Resmetirom is a safe medication with good tolerability in regard to the side effect profile for the first 3 months. Most patients were able to gain insurance approval but delays in dispensing and insurance requirements of invasive fibrosis testing to obtain approval were observed.

Read More arrow

Risk Prediction in Patients With Metabolic Dysfunction-Associated Steatohepatitis Using Natural Language Processing

July 2025

CONCLUSION: We described a cohort of real-world MASH patients using a new NLP algorithm and found several potential predictors of progression to all-cause mortality, cirrhosis, and liver transplantation. The use of NLP to characterize these patients can help support the development of future interventional trials in MASH.

Read More arrow

Deep learning-based method for grading histopathological liver fibrosis in rodent models of metabolic dysfunction-associated steatohepatitis

July 2025

INTRODUCTION: Metabolic dysfunction-associated steatohepatitis (MASH) is a significant liver disease that can lead to cirrhosis and liver cancer. Accurate assessment of liver fibrosis is crucial for diagnosis, prognosis, and informed treatment decision-making. Staging of liver fibrosis in MASH is based on Kleiner's score, which categorizes fibrosis based on its location within the liver as observed microscopically. This scoring system is part of a standard clinical research network and relies...

Read More arrow

Non-invasive tests for resmetirom treatment fail to accurately define the target population: Evidence from a biopsy-proven MASLD cohort

July 2025

CONCLUSION: The NITs defined for identifying the target population for resmetirom demonstrated poor performance in accurately detecting or excluding eligible patients. Therefore, performing a liver biopsy before starting resmetirom treatment will prevent unnecessary increases in cost and significantly reduce the economic burden of the treatment.

Read More arrow

Herbal mixture of Platycodon grandiflorum, Cinnamomum cassia, and Asiasarum sieboldii extracts protects against NASH progression via regulation of hepatic steatosis, inflammation, and apoptosis

July 2025

CONCLUSION: The FPC diet combined with HFCS induced a NASH mouse model that closely mimics the relevant pathology of human NASH within 6 months, BS012 markedly attenuated these pathological features, with the observed protective effects attributed to the reduction of hepatic steatosis through modulation of ChREBP-α- and AMPK-mediated lipid synthesis and fatty acid oxidation pathways. In addition, BS012 suppressed the TLR-4/NF-κB signaling pathway, thereby alleviating inflammation, as well as...

Read More arrow

Evaluation of Serum L-FABP as a Biomarker and Hepatoprotective Effect of L-FABP Using Wild-Type and Human L-FABP Chromosome Transgenic Mice

July 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are the major prevalent liver diseases and growing public health problems worldwide. Because MASLD/MASH is known as a risk for progression to cirrhosis and development of hepatocellular carcinoma, therapeutic approaches and biomarkers that reflect the presence and progression of the disease are needed. In recent years, the usefulness of serum L-FABP levels has been...

Read More arrow

Injinoryeong-San Attenuates Metabolic Dysfunction-associated Steatohepatitis via Regulation of YAP/TAZ-Signaling Pathway

July 2025

CONCLUSION: IJO exhibits significant therapeutic potential against MASH by simultaneously targeting key pathological processes, including lipid dysregulation, oxidative stress, inflammation, fibrosis, and apoptosis. These multi-targeted effects are mechanistically linked to suppression of the YAP/TAZ signaling pathway, suggesting IJO as a promising candidate for further development as a hepatoprotective agent.

Read More arrow

Clinical and Biochemical Features of Diagnosed and Undiagnosed Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

July 2025

CONCLUSIONS: The demographics, metabolic co-morbidities, and severity of liver disease differ in diagnosed versus undiagnosed MASLD patients.

Read More arrow

The Use of Technology Platforms for Nutrition Education in Cirrhosis: A Cross-Sectional Study of Patients' Acceptability and Capabilities

July 2025

CONCLUSION: Patients with cirrhosis are generally receptive to technology-based nutrition education, though barriers may include lower technological proficiency and a negative attitude toward the Internet. Enhancing patients' technological skills could increase their willingness to use technology for educational purposes, particularly among ALD patients.

Read More arrow

PNPLA3 I148M variant links to adverse metabolic traits in MASLD during fasting and feeding

July 2025

CONCLUSIONS: Our findings suggest a dichotomous pattern of increased hepatic lipid storage during feeding and excessive lipid oxidation during fasting, which exceeds metabolic capacity, inducing cellular toxicity in PNPLA3 GG carriers. This interplay fuels a detrimental fasting/non-fasting cycle, thus pointing to the need for preventive strategies.

Read More arrow

Comparison of the magnetic resonance elastography and FIB-4 (MEFIB) Index and vibration-controlled transient elastography for significant metabolic dysfunction-associated steatotic liver disease fibrosis

July 2025

CONCLUSIONS: In patients with MASLD, simple clinical and biochemical parameters may provide an alternative to predict significant fibrosis based on the MEFIB score. This may be useful in non-tertiary centres where VCTE and MRE are not routinely available.

Read More arrow

A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis

July 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions to prevent adverse disease outcomes. The principal determinant of MASH outcomes is the liver fibrosis stage. The prevalence of MASH is higher among people living with obesity and/or type 2 diabetes, with MASH with moderate to advanced fibrosis affecting one in six adults. Delivering a paradigm shift...

Read More arrow

Resolvin D1-mediated cellular crosstalk protects against MASH

July 2025

CONCLUSIONS: RvD1 reduced hepatocyte death and DAMP production by alleviating ER stress-mediated apoptosis, leading to decreased activation of KCs, T cells, and HSCs. This study highlights the novel role of RvD1-mediated cellular crosstalk among different liver cells in MASH.

Read More arrow

Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel

July 2025

CONCLUSIONS: The survey underscores the substantial underdiagnosis of MASH and the reliance on non-invasive diagnostic methods in Germany. The lack of approved treatments necessitates a focus on lifestyle modifications and comorbidity management. The Delphi panel's insights call for enhanced screening, early detection and standardised algorithms to improve patient outcomes.

Read More arrow

Meta-analysis: Histological severity of biopsy-proven metabolic dysfunction-associated steatotic liver disease in pediatric patients

July 2025

The burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in children and adolescents. However, the severity of disease at diagnosis by liver biopsy remains uncertain and has not been systematically evaluated. We conducted a systematic review and meta-analysis to determine the prevalence of metabolic dysfunction-associated steatohepatitis (MASH), significant and advanced fibrosis in this population. PubMed and Embase databases were systematically searched (from...

Read More arrow

The Liver in Diabetes and Metabolic Syndrome

July 2025

A bidirectonal relationship between insulin resistance, diabetes and metabolic dysfunction-associated steatotic liver disease exists. In those with metabolic syndrome, impairments of glucose and lipid metabolism lead to increased liver fat, necroinflammation (steatohepatitis) and subsequent hepatic fibrosis. An integrated perspective and heightened awareness of metabolic dysfunction associated steatotic liver disease is critical to tempering the rising epidemic metabolic dysfunction associated...

Read More arrow

Metabolic Dysfunction-Associated Steatotic Liver Disease at Quantitative US: International Prospective Study

July 2025

Background Quantitative US is promising in assessing metabolic dysfunction-associated steatotic liver disease (MASLD), but prospective multicenter studies are lacking. Purpose To evaluate the diagnostic performance of quantitative US in assessing MASLD and metabolic dysfunction-associated steatohepatitis (MASH). Materials and Methods This prospective study included participants with MASLD from tertiary hospitals in China and Korea, undergoing multiparametric US from August 2021 to December 2023....

Read More arrow

ORP2 regulates free cholesterol accumulation in hepatocytes during MASH

July 2025

CONCLUSIONS: Our results suggest that impaired cholesterol trafficking may exacerbate the deposition of cholesterol crystals in hepatocytes, promoting the development of metabolic dysfunction-associated steatohepatitis.

Read More arrow